ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Cabaletta Bio, Inc. Investors with Losses to Secure Counsel Before Important April 29 Deadline in Securities Class Action – CABA
19 avr. 2022 17h15 HE
|
The Rosen Law Firm PA
NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cabaletta Bio, Inc. (NASDAQ: CABA): (i) pursuant and/or...
AXIM Biotech Develops Rapid Quantitative Tear Test for MMP-9, An Inflammatory Biomarker of Dry Eye Disease
08 mars 2022 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye...
Worldwide Diagnostic Biomarkers Market Size to Reach $95.1 Billion by 2028 - Use of Biomarkers to Give Accurate and Consistent Results Over Conventional Diagnostic Tools Drives the Market – Vantage Market Research
22 févr. 2022 08h46 HE
|
Vantage Market Research
WASHINGTON, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research’s recent analysis of the Global Diagnostic Biomarkers Market finds that because of huge advancement in diagnostic tools, they...
AXIM Biotech Announces New Milestones in Preparation of Dry Eye Disease Diagnostics Launch
15 févr. 2022 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
AXIM is driven to positively transform the state of Dry Eye Disease (DED) testing and diagnosis The company will deploy industry leader IUL’s state-of-the-art iPeak readers Company Adds Veteran Lab...
EDENLUX Launches Campaign for Otus, the Personal EYE-Trainer
17 nov. 2021 00h00 HE
|
EDENLUX
CYPRESS, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Otus, created by EDENLUX, has launched a campaign through Indiegogo. Otus is a personal eye-trainer that is made for the purpose of training...
InvestorBrandNetwork Announces The Dealmaker Show Interview with Tryp Therapeutics Inc. CEO Greg McKee
03 août 2021 08h00 HE
|
InvestorBrandNetwork (IBN)
LOS ANGELES, Aug. 03, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities, today announces...
Aegis Sciences Announces CDC Contract to Provide Genomic Sequencing of SARS-CoV-2 to Aid Public Health Response to COVID-19
16 mars 2021 09h00 HE
|
Aegis Sciences Corporation
NASHVILLE, Tenn., March 16, 2021 (GLOBE NEWSWIRE) -- Aegis Sciences Corporation, a leading healthcare company that provides clinically innovative COVID-19 and medication compliance testing services,...
AIM ImmunoTech to Present at the Q1 Virtual Investor Summit on March 24th
11 mars 2021 07h00 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., March 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech, will be...
Pan-Biome Pharmaceuticals, Inc reports positive results in preclinical trial of Inflammatory Bowel Disease: oral drug shows strong effect in modulating the gut microbiome
24 févr. 2021 10h00 HE
|
Pan-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Pan-Biome Pharmaceuticals, Inc, a Vancouver based preclinical biopharmaceutical company focused on chronic inflammatory and autoimmune...
Sorman·Attali·Anholt “Seoul has shown 'Safe City' capabilities in the COVID-19 era” reports Republic of Korea news agency Newsis
29 oct. 2020 10h55 HE
|
Newsis
Seoul City Hall, International Forum on 'Urban leadership in the Global Era' Guy Sorman "Seoul needs to be promoted as a 'safe city' to the world"Jacques Attali "Seoul has responded flexibly to...